Patients' access to biologics in rheumatoid arthritis: A comparison between Portugal and other European countries

European Journal of Health Economics

Volumn 14, Issue 6, 2013, Pages 875-885

  Laires, P A ^a   Exposto, F ^b   Mesquita, R ^a   Martins, A P ^a   Cunha Miranda, L ^c   Fonseca, J E ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b IQVIA   (United States)

^c INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

^d UNIVERSITY OF LISBON   (Portugal)

Author keywords

Biologics; Portugal; Rheumatoid arthritis; Treatment access

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB;

ARTICLE; AUSTRIA; BELGIUM; CONTROLLED STUDY; DENMARK; DRUG COST; DRUG MARKETING; DRUG USE; FINLAND; FRANCE; FUNDING; GERMANY; GROSS NATIONAL PRODUCT; HEALTH CARE ACCESS; HUMAN; IRELAND; ITALY; NETHERLANDS; NORWAY; PATIENT COMPLIANCE; PORTUGAL; PRIORITY JOURNAL; QUALITY CONTROL; RHEUMATOID ARTHRITIS; SPAIN; SWEDEN; SWITZERLAND; UNITED KINGDOM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; EUROPE; HEALTH EXPENDITURES; HEALTH SERVICES ACCESSIBILITY; HUMANS; METHOTREXATE; PORTUGAL; SOCIOECONOMIC FACTORS;

EID: 84888436330     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-012-0432-5     Document Type: Article

References (32)

1. Chen, Y.F.; Jobanputra, P.; Barton, P.; et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. 10(42), 3-4 (2006)
2. Kvien, T.K.: Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22, 1-12 (2004)
3. Matos, A.A.; Branco, J.C.; Canas Silva, J.; Viana Queiroz, M.; Pádua, F.: Inquérito epidemiológico de doenças reumáticas numa amostra da população portuguesa (resultados preliminares). Acta Reumatol. Port. 16(1), 98 (1991)
4. National Institute for Health and Clinical Excellence: Rheumatoid arthritis - National clinical guideline for management and treatment in adults. NICE, London (2009)
5. Singh, J.A.; Christensen, R.; Wells, G.A.; et al.: Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Review). Cochrane Database Syst. Rev. (4) (2009). doi: 10.1002/14651858.CD007848.pub2
6. Smolen, J.S.; Landewé, R.; Breedveld, F.C.; et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964-975 (2010). doi: 10.1136/ard.2009.126532
7. Jönsson, B.; Kobelt, G.; Smolen, J.: The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur. J. Health Econ. 8, 61-86 (2008). doi: 10.1007/s10198-007-0089-7
8. Kobelt, G.; Kasteng, F.: Access to innovative treatments in rheumatoid arthritis in Europe. A report prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA). http://www.lif.se/default.aspx?id= 44400 (2009). Accessed December 2011
9. Miltenburger, C.; Gunther, O.; Justo, N.; et al.: A survey of barriers to treatment access in rheumatoid arthritis in France, Germany, Italy, Spain and the UK (2009). Accessed December 2011
10. Emery, P.; Van Vollenhoven, R.; Ostergaard, M.; et al.: Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann. Rheum. Dis. 68(4), 456-459 (2009). doi: 10.1136/ard.2008.100362
11. Cruz, M.; Fonseca, J.E.; Branco, J.C.: Artrite reumatóide: paradigma das doenças reumáticas crónicas. Tecnologia Médica 2, 2-11 (2002)
12. Cruz, M.; Fonseca, J.E.; Branco, J.C.: Três anos de administração de etanercept e infliximab a doentes com artrite reumatóide refractária - avaliação clínica e radiográfica e segurança. Acta Reumatol. Port. 29, 21-32 (2004)
13. Barcelos, A.; Salvador, M.J.; da Silva, J.A.; et al.: Indução de auto anticorpos durante tratamento prolongado com infliximab em doentes com artrite reumatóide. Acta Reumatol. Port. 29, 161-167 (2004)
14. Grupo de Estudos de Artrite Reumatóide da Sociedade Portuguesa de Reumatologia: Análise de 376 doentes com Artrite Reumatóide submetidos a terapêutica biológica registados na base de dados de agentes biológicos da Sociedade Portuguesa de Reumatologia. Acta Reumatol. Port. 30, 63-71 (2005)
15. Canhão, H.; Faustino, A.; Martins, F.; et al.: Reuma.pt - the rheumatic diseases portuguese register. Acta Reumatol. Port. 36(1), 45-56 (2011)
16. WHO Collaborating Centre for Drug Statistics Methodology: WHODD guidelines for ATC classification and DDD assignment 2010. Norwegian Institute of Public Health. http://www.whocc.no/atc-ddd-index (2010). Accessed January 2011
17. United Nations Development Programme: Human Development Report 2007/2008. http://hdrstats.undp.org/en/indicators/default.html (2007)
18. United Nations Development Programme: Human Development Report 2010. http://hdr.undp.org/en/reports/global/hdr2010/chapters/ (2010)
19. Eurostat database Directorate-General (DG) of the European Commission. http://epp.eurostat.ec.europa.eu (1953)
20. World Economic Outlook Database, April 2011. International Monetary Fund. http://www.imf.org/external/pubs/ft/weo/2011/01/weodata/weoselgr.aspx (2011). Accessed April 2011
21. Observatório Do Medicamento e Produtos de Saúde: Consumo de Medicamentos em meio hospitalar. In. INFARMED (2010)
22. MIDAS Database. IMS Health. Accessed January 2011
23. Orlewska, E.; Ancuta, I.; Anic, B.; et al.: Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med. Sci. Monit. 17(4), SR1-SR13 (2011)
24. Rousseeuw, P.J.: Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. Computational and applied mathematics. J. Comput. Appl. Math. (1987). doi: 10.1016/0377-0427(87)90125-7
25. Associação Nacional dos Doentes com Artrite Reumatóide: Impacto dos medicamentos biológicos na qualidade de vida dos doentes. Paper presented at the Plataforma Mais Saúde, INFARMED, Portugal, 22 Nov 2011
26. Cunha-Miranda, L.; Santos, H.; Ferreira, J.; et al.: Finding Rheumatoid Arthritis Impact on Life (FRAIL Study): economic burden. Acta Reumatol. Port. (37), 134-142 (2012)
27. Gulácsi, L.: Future challenges for health economics and health technology assessment of biological drugs. Eur. J. Health Econ. 11(3), 235-238 (2010). doi: 10.1007/s10198-010-0246-2
28. Ramiro, S.; Canhão, H.; Branco, J.C.: EpiReumaPt protocol - Portuguese epidemiologic study of the rheumatic diseases. Acta Reumatol. Port. 35(3), 384-390 (2010)
29. Drosos, A.A.; Lanchbury, J.S.; Panayi, G.S.; et al.: Rheumatoid arthritis in greek and british patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum. 35(7), 745-748 (1992). doi: 10.1002/art.1780350705
30. Salvarani, C.; Macchioni, P.L.; Mantovani, W.; et al.: HLA-DRB1 alleles associated with rheumatoid arthritis in northern Italy: correlation with disease severity. Br. J. Rheumatol. 37, 165-169 (1998)
31. Ronda, E.; Ruiz, M.T.; Pascual, E.; et al.: Differences between Spanish and British patients in the severity of rheumatoid arthritis: comment on the article by Drosos et al. Arthritis Rheum. 37(1), 147-148 (1994). doi: 10.1002/art.1780370125
32. Benazet, J.F.; Reviron, D.; Mercier, D.; et al.: HLADRB1 alleles associated with rheumatoid arthritis in southern France: absence of extraarticular disease despite expression of the shared epitope. J. Rheumatol. 22, 607-610 (1995)